Scott Edward Schaus

USPTO Granted Patents = 13 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

Northeastern University

patents

2 out of 61

Boston Medical Center Corporation

patents

4. 1 out of 15,475

University of California

patents

5. 1 out of 24

Fundacao Oswaldo Cruz

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12251372 - Antileishmanial compounds, compositions and use thereof (2025-03-18),

2. 11458132 - Quinolin-2(1H)-one inhibitors of Late SV40 Factor (2022-10-04),

3. 11420977 - Late SV40 (LSF) inhibitors (2022-08-23),

4. 11242353 - Heterocyclic LSF inhibitors and their uses (2022-02-08),

5. 10392398 - Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics (2019-08-27),

6. 10314810 - Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics (2019-06-11),

7. 10258600 - Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics (2019-04-16),

8. 9815845 - Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics (2017-11-14),

9. 9802948 - Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics (2017-10-31),

10. 9597325 - Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics (2017-03-21),

11. 9567331 - Pyridopyrimidinone inhibitors of viruses (2017-02-14),

12. 9399644 - [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer (2016-07-26),

13. 9175001 - [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer (2015-11-03),

Title: The Innovations of Scott Edward Schaus

Introduction

Scott Edward Schaus is a prominent inventor based in Boston, MA, known for his significant contributions to the field of medicinal chemistry. With a total of 13 patents to his name, Schaus has made remarkable advancements in the development of compounds aimed at treating various diseases, including cancer and leishmaniasis.

Latest Patents

Among his latest patents are the "Antileishmanial compounds, compositions and use thereof," which provides innovative solutions for combating leishmaniasis through novel compounds and compositions. Another notable patent is the "Quinolin-2(1H)-one inhibitors of Late SV40 Factor," which focuses on compositions and methods for treating cancer, particularly hepatocellular carcinoma (HCC). This invention highlights the use of small-molecule compounds to inhibit tubulin acetylation, thereby affecting cell migration and compaction.

Career Highlights

Schaus has had a distinguished career, working at esteemed institutions such as Boston University and Northeastern University. His research has significantly impacted the scientific community, particularly in the areas of cancer treatment and infectious diseases.

Collaborations

Throughout his career, Schaus has collaborated with notable colleagues, including Ulla Hansen and Joshua A Bishop, contributing to a rich exchange of ideas and innovations in his field.

Conclusion

Scott Edward Schaus exemplifies the spirit of innovation in medicinal chemistry, with his patents paving the way for new treatments and therapies. His work continues to inspire future advancements in the medical field.

This text is generated by artificial intelligence and may not be accurate.